Unstable angina pectoris

New England Journal of Medicine

Volumn 342, Issue 2, 2000, Pages 101-114

  Yeghiazarians, Yerem ^a   Braunstein, Joel B ^a   Askari, Arman ^a   Stone, Peter H ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN DERIVATIVE;

CARDIOVASCULAR RISK; DISEASE SEVERITY; HEART MUSCLE REVASCULARIZATION; HEMODYNAMIC MONITORING; HUMAN; OUTPATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THORAX PAIN; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS;

ADRENERGIC BETA-ANTAGONISTS; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CALCIUM CHANNEL BLOCKERS; ELECTROCARDIOGRAPHY; EXERCISE TEST; FIBRINOLYTIC AGENTS; HUMANS; NITROGLYCERIN; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TREATMENT FAILURE;

EID: 0034642591     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200001133420207     Document Type: Review

References (140)

1. Graves E. National Hospital Discharge Survey. Annual survey 1996. Series 13, no. 4. Washington, D.C.: National Center for Health Statistics, 1998.
2. Lincoff AM, Tcheng IE, Califf RM, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Circulation 1999;99:1951-8.
3. Gibson CM, Goel M, Cohen DJ, et al. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. J Am Coll Cardiol 1998;32:28-34.
4. Braunwald E. Unstable angina: a classification. Circulation 1989;80: 410-4.
5. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988;78:1157-66.
6. Fishbein MC, Siegel RJ. How big are coronary atherosclerotic plaques that rupture? Circulation 1996;94:2662-6.
7. Ambrose JA, Winters SL, Arora RR, et al. Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol 1986; 7:472-8.
8. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988;12:56-62.
9. Alison HW, Russell RO Jr, Mantle JA, Kouchoukos NT, Moraski RE, Rackley CE. Coronary anatomy and arteriography in patients with unstable angina pectoris. Am J Cardiol 1978;41:204-9.
10. Fuster V, Frye RL, Connolly DC, Danielson MA, Elveback LR, Kurland LT. Arteriographic patterns early in the onset of coronary syndromes. Br Heart J 1975;37:1250-5.
11. Ambrose JA, Winters SL, Stern A, et al. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol 1985; 5:609-16.
12. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993;69:377-81.
13. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989;2:941-4.
14. Fuster V, Lewis A. Conner Memorial Lecture: mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994;90:2126-46. [Erratum, Circulation 1995;91:256.]
15. Théroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. Circulation 1998;97:1195-206.
16. Cheng GC, Loree HM, Kamm RD, Fishbein MC, Lee RT. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions: a structural analysis with histopathological correlation. Circulation 1993; 87:1179-87.
17. Henney AM, Wakeley PR, Davies MJ, et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A 1991;88:8154-8.
18. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-50.
19. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation 1994;90:775-8.
20. Welgus HG, Campbell EJ, Cury JD, et al. Neutral metalloproteinases produced by human mononuclcar phagocytes: enzyme profile, regulation, and expression during cellular development. J Clin Invest 1990;86:1496-502.
21. Galis ZS, Sukhova GK, Kranzhöfer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci U S A 1995;92:402-6.
22. Fernàndez-Ortiz A, Badimón JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994;23: 1562-9.
23. Moreno PR, Bernardi VH, Lopez-Cuéllar J, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina: implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996;94:3090-7.
24. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Sci U S A 1989;86:2839-43.
25. Patrono C, Renda G. Platelet activation and inhibition in unstable coronary syndromes. Am J Cardiol 1997;80:17E-20E.
26. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993;82:513-20.
27. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-11.
28. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425-8.
29. Cannon CP, McCabe CH, Stone PH, et al. Circadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (the TIMI Registry and TIMI IIIB). Am J Cardiol 1997;79:253-8.
30. Curfman GD. Is exercise beneficial - or hazardous - to your heart? N Engl J Med 1993;329:1730-1.
31. Alpert JS. Coronary vasomotion, coronary thrombosis, myocardial infarction and the camel's back. J Am Coll Cardiol 1985;5:617-8.
32. Meredith IT, Yeung AC, Weidinger FF, et al. Role of impaired endothelium-dependent vasodilation in ischemic manifestations of coronary artery disease. Circulation 1993;87:Suppl V:V-56-V-66.
33. Wieczorek I, Haynes WG, Webb DJ, Ludlam CA, Fox KAA. Raised plasma endothelin in unstable angina and non-Q wave myocardial infarction: relation to cardiovascular outcome. Br Heart J 1994;72:436-41.
34. Watanabe T, Suzuki N, Shimamoto N, Fujino M, Imada A. Contribution of endogenous endothelin to the extension of myocardial infarct size in rats. Circ Res 1991;69:370-7.
35. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986;314:488-500.
36. Nobuyoshi M, Tanaka M, Nosaka H, et al. Progression of coronary atherosclerosis: is coronary spasm related to progression? J Am Coll Cardiol 1991;18:904-10.
37. Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core: a frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996;93:1354-63.
38. Flugelman MY, Virmani R, Correa R, et al. Smooth muscle cell abundance and fibroblast growth factors in coronary lesions of patients with nonfatal unstable angina: a clue to the mechanism of transformation from the stable to the unstable clinical state. Circulation 1993;88:2493-500.
39. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration cooperative study. N Engl J Med 1983;309:396-403.
40. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 1985;313:1369-75.
41. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-11.
42. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106. [Erratum, BMJ 1994;308:1540.]
43. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
44. Eisenberg MJ, Topol EJ. Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. Arch Intern Med 1996;156:1506-10.
45. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-30.
46. Wallentin LC, Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. J Am Coll Cardiol 1991;18:1587-93.
47. Braunwald E, Mark DB, Jones RH, et al. Unstable angina: diagnosis and management. Clinical practice guideline. No. 10. Rockville, Md.: Department of Health and Human Services, 1994. (AHCPR publication no. 94-0602.)
48. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. Circulation 1990;82:17-26.
49. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
50. Moussa I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999;99:2364-6.
51. Madan M, Berkowitz SD, Tcheng JE. Glycoprotein IIb/IIIa integrin blockade. Circulation 1998;98:2629-35.
52. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
53. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
54. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
55. 3 blockade with percutaneous coronary intervention. JAMA 1997;278:479-84.
56. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8.
57. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
58. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
59. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-35. [Erratum, Lancet 1997;350:744.]
60. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
61. Lincoff AM, Tcheng JE, Califf RM, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Circulation 1999;99:1951-8.
62. Hamm CW, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med 1999;340:1623-9.
63. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97. [Erratum, N Engl J Med 1998; 339:415.]
64. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-505.
65. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43
66. The PARAGON Investigators. An international, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998;97:2386-95.
67. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337: 688-98. [Erratum, N Engl J Med 1997;337:1567.]
68. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996;276:811-5.
69. Klein LW, Wahid F, VandenBerg BJ, Parrillo JE, Calvin JE. Comparison of heparin therapy for < or = 48 hours to > 48 hours in unstable angina pectoris. Am J Cardiol 1997;79:259-63.
70. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
71. Eisenberg PR. Novel antithrombotic strategies for the treatment of coronary artery thrombosis: a critical appraisal. J Thromb Thrombolysis 1995;1:237-49.
72. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-8.
73. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-8.
74. Klein W, Buchwald A, Hillis WS, et al. Fragmin in unstable angina pectoris of in non-Q-wave acute myocardial infarction (the FRIC study). Am J Cardiol 1997;80(5A):30E-34E.
75. Swahn E, Wallentin L. Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). Am J Cardiol 1997, 80(5A):25E-29E.
76. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in unstable coronary artery disease study. Circulation 1997;96:61-8. [Erratum, Circulation 1998;97:413.]
77. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.
78. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) IIB trial. Circulation 1999;100:1593-601.
79. The Thrombolysis in Myocardial Infarction (TIMI) IIA Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI IIA. J Am Coll Cardiol 1997;29:1474-82.
80. Organisation to Assess Strategics for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant birudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999;353:429-38.
81. Thrombin Inhibition in Myocardial Ischaemia (TRIM) Study Group. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients: a double-blind, randomized, dose-finding study. Eur Heart J 1997;18:1416-25.
82. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-52.
83. Cohen MC, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS Trial. Circulation 1994;89:81-8.
84. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dosed warfarin-with aspirin with aspirin after myocardial infarction. Lancet 1997;330:389-96.
85. Williams MJA, Morison IM, Parker JH, Stewart RAH. Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: prelimenary study. J Am Coll Cardiol 1997;30: 364-9.
86. Anand SS, Yusuf S, Pogue J, Weitz JI, Flather M. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: Organization to Assess Strategies for Ischemic Syndromes (OASIS) pilot study results. Circulation 1998;98:1064-70.
87. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB Trial. Circulation 1994;89: 1545-56.
88. Bovill EG, Tracy RP, Knatterud GL, et al. Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina [Thrombolysis in Myocardial Ischemia, phase IIIB trial). Am J Cardiol 1997;79:391-6.
89. Ambrose JA, Almeida OD, Sharma SK, et al. Adjunctive thrombolytic therapy during angioplasty for ischemic rest angina: results of the TAUSA Trial. Circulation 1994;90:69-77.
90. Bar FW, Verheugt FW, Col J, et al. Thrombolysis in patients with unstable angina improves the angiographic but not the clinical outcome: results of UNASEM, a multicenter, randomized, placebo-controlled, clinical trial with anistreplase. Circulation 1992;86:131-7.
91. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1 000 patients. Lancet 1994;343:311-23. [Erratum, Lancet 1994;343:742.]
92. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesbro J. Insights into the pathogenesis of the acute ischemic syndromes. Circulation 1988;77:1213-20.
93. Telford AM, Wilson C. Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981; 1:1225-8.
94. Gottlieb SO, Weisfeldt ML, Ouyang P, et al. Effect of the addition of propranolol to therapy with nifedipine for unstable angina pectoris: a randomized, double-blind, placebo-controlled trial. Circulation 1986;73:331-7.
95. Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT]. Am J Cardiol 1987;60:18A-25A.
96. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 1988;260:2259-63.
97. Prisant LM, Houghton JL, Bottini PB, Carr AA. Unstable angina: pharmaceutical versus invasive therapy. Postgrad Med 1994;96:88-95.
98. Thadani U, Opie LH. Nitrates for unstable angina. Cardiovasc Drugs Thcr 1994;8:719-26.
99. Fitzgerald DJ, Roy L, Robertson RM, FitzGerald GA. The effects of organic nitrates on prostacyclin biosynthesis and platelet function in humans. Circulation 1984;70:297-302.
100. Munzel T, Kurz S, Heitzer T, Harrison DG. New insights into mechanisms underlying nitrate tolerance. Am J Cardiol 1996;77:24C-30C.
101. Bassenge E, Fink N, Skatchkov M, Fink B. Dietary supplement with vitamin C prevents nitrate tolerance. J Clin Invest 1998;102:67-71.
102. Ferrari R. Prognosis of patients with unstable angina or acute myocardial infarction treated with calcium channel antagonists. Am J Cardiol 1996;77:22D-25D.
103. Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989;299: 1187-92.
104. Théroux P, Taeymans Y, Morissette D, Bosch X, Pelletier GB, Waters DD. A randomized study comparing propranolol and diltiazem in the treatment of unstable angina. J Am Coll Cardiol 1985;5:717-22.
105. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-92.
106. Effect of verapamil on mortality and major events after acute myocardial infarction. (the Danish Verapamil Infarction Trial II - DAVIT II), Am J Cardiol 1990;66:779-85.
107. Luchi RJ, Scott SM, Deupree RH, Principal Investigators and Their Associates of Veterans Administration Cooperative Study No. 28. Comparison of medical and surgical treatment for unstable angina pectoris: results of a Veterans Administration cooperative study. N Engl J Med 1987;316: 977-84.
108. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217-25.
109. Pocock SJ, Henderson RA, Rickards AF, et al. Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. Lancet 1995;346:1184-9.
110. Marzocchi A, Piovaccari G, Marrozzini C, et al. Results of coronary stenting for unstable versus stable angina pectoris. Am J Cardiol 1997;79: 1314-8.
111. Myler RK, Shaw RE, Stertzer SH, et al. Unstable angina and coronary angioplasty. Circulation 1990;82:Suppl II:II-88-II-95.
112. Bentivoglio LG, Detre K, Yeh W, Williams DO, Kelsey SF, Faxon DP. Outcome of percutaneous transluminal coronary angioplasty in subtypes of unstable angina pectoris: a report of the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol 1994;24:1195-206.
113. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
114. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated stent with balloon angioplasty in selected patients with coronary artery disease. Lancet 1998;352:673-81. [Erratum, Lancet 1998;352:1478.]
115. Shimada K, Kawarabayashi T, Komatsu R, Sakamoto T, Shimizu Y, Yoshikawa J. Efficacy and safety of early coronary stenting for unstable angina. Cathet Cardiovasc Diagn 1998;43:381-5.
116. Chauhan A, Vu E, Ricci DR, et al. Multiple coronary stenting in unstable angina: early and late clinical outcomes. Cathet Cardiovasc Diagn 1998;43:11-6.
117. Madan M, Marquis JF, de May MR, et al. Coronary stenting in unstable angina: early and late clinical outcomes. Can J Cardiol 1998;14: 1109-14
118. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996;93:215-22.
119. Leon MB, Baim DS, Popma JJ, et al. Clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998;339:1665-71.
120. Hillis WS. The continuing debate: conservative or interventional therapy for unstable coronary artery disease. Am J Cardiol 1997;80:51E-54E.
121. Pettijohn TL, Doyle T, Spickerman AM, Watson LE, Riggs MW, Lawrence ME. Usefulness of positive troponin-T and negative creatine kinase levels in identifying high-risk patients with unstable angina pectoris. Am J Cardiol 1997;80:510-1.
122. Lindahl B, Venge P, Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. Circulation 1996;93:1651-7.
123. Amman EM, Sacks DB, Rifai N, McCabe CH, Cannon CP, Braunwald E. Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) IIA substudy. J Am Coll Cardiol 1998; 31:32630.
124. Amman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335:1342-9.
125. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI IIA substudy. J Am Coll Cardiol 1998;31:1460-5.
126. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99:855-60.
127. Cannon CP, McCabe CH, Stone PH, et al. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. J Am Coll Cardiol 1997;30:133-40.
128. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA 1999; 281:707-13.
129. Stone PH, Thompson B, Zaret BL, et al. Factors associated with failure of medical therapy in patients with unstable angina and non-Q wave myocardial infarction: a TIMI-IIIB database study. Eur Heart J 1999;20: 1084-93.
130. Haines DE, Raabe DS, Gundel WD, Wackers FJ. Anatomic and prognostic significance of new T-wave inversion in unstable angina. Am J Cardiol 1983;52:14-8.
131. Sclarovsky S, Davidson E, Lewin RF, Strasberg B, Arditti A, Agmon J. Unstable angina pectoris evolving to acute myocardial infarction: significance of ECG changes during chest pain. Am Heart J 1986;112:459-62.
132. Gorgels APM, Vos MA, Mulleneers R, de Zwaan C, Bar FWHM, Wellens HJJ. Value of the electrocardiogram in diagnosing the number of severely narrowed coronary arteries in rest angina pectoris. Am J Cardiol 1993;72:999-1003.
133. Stratmann HG, Younis LT, Wittry MD, Amato M, Miller DD. Exercise technetium-99m myocardial tomography for the risk stratification of men with medically treated unstable angina pectoris. Am J Cardiol 1995; 76:236-40.
134. Madsen JK, Stubgaard M, Utne HE, et al. Prognosis and thallium-201 scintigraphy in patients admitted with chest pain without confirmed acute myocardial infarction. Br Heart J 1988;59:184-9.
135. Stratmann HG, Tamesis BR, Younis LT, Wittry MD, Amato M, Miller DD. Prognostic value of predischarge dipyridamole technetium 99m sestamibi myocardial tomography in medically treated patients with unstable angina. Am Heart J 1995;130:734-40.
136. Jain D, Thompson B, Wackers FJT, Zaret BL. Relevance of increased lung thallium uptake on stress imaging in patients with unstable angina and non-Q wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI)-IIIB Study. J Am Coll Cardiol 1997;30:421-9.
137. Stone PH. The role of ST-segment monitoring in the management of patients with unstable angina. In: Rutherford JD, ed. Unstable angina pectoris. New York: Marcel Dekker, 1991:105-20.
138. Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med 1998;338:1785-92. [Erratum, N Engl J Med 1998;339:1091.]
139. FRagmin and Fast Revascularization during Instability in Coronary artery disease (FRISC II) Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354:701-7.
140. Zaacks SM, Liebson PR, Calvin JE, Parrillo JE, Klein LW. Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications? J Am Coll Cardiol 1999;33:107-18.